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Abstract
Objective: The California Lupus Surveillance Project (CLSP) is a population-based registry of 
individuals with SLE residing in San Francisco County, California from 2007–2009, with a special 
focus on Asians/Pacific Islanders (API) and Hispanics. We used retrospective CLSP data to 
analyze racial/ethnic differences in lupus manifestations and in the timing and risk of developing 
severe manifestations.
Methods: 724 patients with SLE were retrospectively identified. Prevalence ratios (PR) of SLE 
manifestations were calculated using Poisson regression models stratified by race/ethnicity and 
adjusted for sex, age at SLE diagnosis, and disease duration. We studied onset of severe SLE 
manifestations after SLE diagnosis using Kaplan-Meier methods to examine time-to-event and 
Cox proportional hazards regressions to estimate hazard ratios (HR). Whites were the referent 
group in all analyses.
Results: Blacks, APIs, and Hispanics had increased prevalence of renal manifestations [PR 1.74 
(95%CI: 1.40–2.16), PR 1.68 (95%CI: 1.38–2.05), PR 1.35 (95%CI: 1.05–1.74)], respectively. 
Furthermore, Blacks had increased prevalence of neurologic manifestations [PR 1.49 (95%CI: 
1.12–1.98)] and both Blacks [PR 1.09 (95%CI: 1.04–1.15)] and APIs [PR 1.07 (95%CI: 1.01–
1.13)] had increased prevalence of hematologic manifestations. Blacks, APIs, and Hispanics, 
respectively, had higher risk of developing lupus nephritis [HR 2.4 (95%CI: 1.6–3.8), HR 4.3 
(95%CI: 2.9–6.4), HR 2.3 (95%CI: 1.4–3.8)] and thrombocytopenia [HR 2.3 (95%CI: 1.1–4.4), 
HR 2.3 (95%CI: 1.3–4.2), HR 2.2 (95%CI: 1.1–4.7)]. APIs and Hispanics had higher risk of 
developing antiphospholipid syndrome [HR 2.5 (95%CI: 1.4–4.4), HR 2.6 (95%CI: 1.3–5.1), 
respectively].
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Conclusions: This is the first epidemiologic study comparing lupus manifestations among four 
major racial/ethnic groups. We found 1) substantial differences in the prevalence of several clinical 
SLE manifestations among racial/ethnic groups, and 2) that Blacks, APIs, and Hispanics are at 
increased risk of developing several severe manifestations following SLE diagnosis.
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease with a 
higher prevalence among women and racial/ethnic minority groups in the United States 
(U.S.). However, despite the growing numbers of Asians/Pacific Islanders (API) and 
Hispanics in the U.S., little is known about the epidemiology of SLE in these populations. 
To produce contemporary population-based estimates of incidence and prevalence among 
various racial/ethnic groups, the Centers for Disease Control and Prevention (CDC) funded 
four SLE registries across the U.S., including two registries in California and New York, 
which focused on Hispanics and Asians. Estimates from the registries showed, relative to 
whites, increased incidence and prevalence of SLE among Blacks (1–4), APIs (2,3), 
Hispanics (2,3), and American Indian/Alaskan Natives (5). Specifically, the California 
Lupus Surveillance Project (CLSP) reported a higher age-standardized incidence and 
prevalence of SLE among Black (15.5 per 100,000 person-years; 241.0 per 100,000 
persons), API (4.1 per 100,000 person-years; 90.5 per 100,000 persons), and Hispanic 
populations (4.2 per 100,000 person-years; 94.7 per 100,000 persons) relative to whites (2.8 
per 100,000 person-years; 55.2 per 100,000 persons) in San Francisco County during the 
period 2007–2009 (3).
There are currently few studies exploring racial/ethnic differences in the clinical presentation 
of SLE or in the development of severe disease manifestations subsequent to SLE diagnosis. 
Previous epidemiologic studies suggest that in comparison to whites, Blacks have a more 
severe presentation of symptoms at the time of diagnosis of SLE and a worse overall 
prognosis (6–8). However, no studies to date have analyzed racial/ethnic differences in 
manifestations of SLE across the four major racial/ethnic populations in the U.S., including 
among APIs and Hispanics. To address this gap, we examined data gathered in the CLSP to 
investigate racial/ethnic differences in the prevalence of SLE manifestations and in the risk 
and timing of development of severe SLE manifestations.
PATIENTS AND METHODS
California Lupus Surveillance Project (CLSP).
The California Department of Public Health (CDPH) collaborated with the University of 
California, San Francisco (UCSF) to conduct the CLSP, as described elsewhere (3). The 
State of California’s Institutional Review Board (IRB) granted a waiver for this public health 
surveillance activity. The project was reviewed and approved by the UCSF Committee on 
Human Research.
Source population/catchment area criteria.
The CLSP includes residents of San Francisco County within the period of 2007 to 2009. 
According to U.S. Census estimates during this time period, San Francisco County averaged 
790,582 residents, with the following racial/ethnic composition: 56% white, 35% API, 7% 
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Black, and 1% American Indian/Alaskan Native (9). Fifteen percent of the San Francisco 
population identified as Hispanic, which is reported separately from race in the Census.
Case definition.
In this analysis, patients were defined as having SLE if they met at least four of the 11 
American College of Rheumatology (ACR) revised classification criteria defined in 1982 
and updated in 1997 (10,11).
Case ascertainment.
Three primary sources within the catchment area provided possible cases of SLE: 1) 
community rheumatology and nephrology clinics, 2) community hospitals, and 3) integrated 
healthcare systems including UCSF, Kaiser Permanente, and the San Francisco Veterans 
Administration Medical Center (VAMC). Potential cases were identified using the 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
diagnostic codes 710.0 (SLE), 695.4 (discoid lupus), 710.8 (other specified connective tissue 
disease), and 710.9 (unspecified connective tissue disease). Secondary sources of possible 
cases of SLE included a commercial laboratory, which was queried for a comprehensive 
panel of SLE-related serologic tests, as described elsewhere (3), and the California Office of 
Statewide Health Planning and Development (OSHPD) hospital discharge database, which 
was queried for patient discharges using similar ICD-9 codes listed above.
Clinical manifestations of SLE.
A defined number of SLE manifestations for each patient was ascertained from the medical 
records and grouped within the following ten categories: mucocutaneous, serositis, 
cardiovascular, pulmonary, gastrointestinal, renal, musculoskeletal, neurologic, hematologic, 
and serologic. The manifestations included under each of these categories are defined in 
Appendix 1.
Severe SLE Manifestations.
We evaluated the following four severe SLE manifestations: lupus nephritis, 
thrombocytopenia, neuropsychiatric lupus, and antiphospholipid syndrome (APS). Because 
the initial chart abstraction did not include the date of first appearance of lupus nephritis, we 
created a surrogate variable to define nephritis. Any one of the following three laboratory 
measurements were used to define onset of lupus nephritis: 24-hour proteinuria > 500mg, 
24-hour urine protein/creatinine ratio > 0.5, or spot protein/creatinine ratio > 0.5. We chose 
this approach to increase the sensitivity of our definition and to ensure that barriers to access 
and timely diagnosis did not bias the results. A positive laboratory result nearest to the date 
of SLE diagnosis was used to define the time of initial lupus nephritis. Thrombocytopenia 
was defined as a documented platelet count below 100,000/mm3 or physician documentation 
of thrombocytopenia that was unexplained by medication effect or other causes. 
Neuropsychiatric manifestations included seizures, psychosis, and acute confusional state, as 
documented in the medical record. APS was diagnosed when there was physician 
documentation of APS. We also evaluated a combined outcome, i.e., development of any of 
lupus nephritis, thrombocytopenia, neuropsychiatric lupus, or APS.
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Independent Variables.
Information regarding sex and race/ethnicity was abstracted from each medical chart. For 
race/ethnicity, patients were classified as non-Hispanic white, non-Hispanic Black, API, or 
Hispanic (any race). Non-Hispanic whites and non-Hispanic Blacks will be referred to as 
whites and Blacks from this point forward. American Indian/Alaskan natives were identified 
but excluded from this analysis due to small sample size (n = 4). Physician-documented age 
at SLE diagnosis was categorized into discrete age groups (≤18, 19–29, 30–39, 40–49, 50+ 
years) to account for the non-linear relationship between age of diagnosis and disease 
manifestations. At the time of chart abstraction, the number of years since physician-
documented date of SLE diagnosis for each subject was calculated from the year of last 
reported clinic visit date; years elapsed since diagnosis were categorized as: ≤5, 6–10, 11–
15, and 16+ years, which approximated quartiles of the distribution.
Statistical Analyses.
Baseline racial/ethnic differences in age at SLE diagnosis and years since SLE diagnosis 
were examined using ANOVA, after determining that the assumptions of normally 
distributed residuals and homoscedasticity were not violated. Racial/ethnic differences in sex 
and SLE manifestation were examined using a chi-square test. Race/ethnicity-stratified 
prevalence ratios (PR) for clinical manifestations of SLE were calculated using a Poisson 
regression model with robust error variances, including the covariates sex, age at SLE 
diagnosis, and years since SLE diagnosis. A Poisson regression model was chosen due to its 
appropriateness for analyzing count data and the rarity of individual manifestations. Kaplan-
Meier survival methods were used to examine the time to onset of severe SLE 
manifestations. Individual survival curves representing separate race/ethnicities were 
compared using the log-rank test. For each severe SLE manifestation, we estimated the risk 
of manifestation onset for race/ethnicity, sex, and age at SLE diagnosis using multivariable 
Cox proportional hazards regression models that modelled the three characteristics 
simultaneously. Higher hazard ratios (HR) indicated a greater risk of developing specific 
manifestations over time. The proportional-hazards assumption based on Schoenfeld 
residuals was validated for appropriateness of use.
For the survival analysis, the baseline was defined as the physician-documented date of SLE 
diagnosis. Subjects who already had evidence of the reported outcome(s) at the time of SLE 
diagnosis were treated as having developed the outcome on day one. Patients were included 
in follow-up until they developed the outcome of interest or were censored at the date of the 
last recorded clinical visit through 2009. A chi-square test was used to evaluate racial/ethnic 
differences in the presence of severe SLE manifestations identified at the date of SLE 
diagnosis.
Given the use of a surrogate variable to define lupus nephritis onset, a sensitivity analysis 
was performed in which only those with subsequently physician-diagnosed lupus nephritis 
were analyzed. All statistical analyses were performed using STATA 13 (12).
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RESULTS
Study population characteristics.
Seven hundred twenty-four patients with SLE residing in San Francisco County between 
2007 and 2009 were retrospectively identified (Table 1). The distribution by race/ethnicity 
was as follows: white (26.2%), Black (18.8%), API (36.9%), and Hispanic (15.5%). API 
patients were predominantly Chinese (49.4%), followed by Filipino (15.4%) and Vietnamese 
(6.7%). Most Hispanic patients had no ethnic origin specified (50.9%), followed by South or 
Central American (except Brazilian) (31.3%) and Mexican (13.4%). Nineteen patients had 
missing race/ethnicity information (2.6%) and seven patients (1.0%) had a missing date of 
last clinic visit. All twenty-six (3.6%) of these patients were excluded from further analysis. 
Females comprised 89.5% of the patients. No statistically significant differences in age at 
SLE diagnosis (p = 0.341) or sex (p = 0.735) were observed by race/ethnicity. Conversely, 
there was a statistically significant difference in the duration of SLE among race/ethnicities, 
with whites more likely to have ≥16 years follow-up from diagnosis (44% compared to 15–
30% for other groups, p < 0.001). With respect to the severe SLE manifestations studied, 
Blacks and APIs had higher prevalence of lupus nephritis (20% and 52%, respectively, 
compared to 13–14% among other groups, p < 0.001) and thrombocytopenia (24% and 39%, 
respectively, compared to 17–19% among other groups, p = 0.009). Neuropsychiatric lupus 
was less common among Hispanics (15% compared to 27–29% among other groups, p = 
0.089), and APS was more common among APIs (43% compared to 18–20% among other 
groups, p = 0.205), although these differences did not meet statistical significance.
Clinical manifestations of SLE.
In comparison to whites, Blacks, APIs, and Hispanics had increased prevalence of renal 
manifestations (PR 1.74, PR 1.68, PR 1.35, respectively; Table 2). Blacks had increased 
prevalence of neurologic manifestations (PR 1.49) and both Blacks and APIs had increased 
prevalence of hematologic manifestations (PR 1.09, PR 1.07, respectively). Because we 
were performing multiple statistical comparisons, we applied a Bonferroni correction (p < 
0.005) when interpreting our p values to reduce the risk of Type 1 errors. After applying this 
correction, the higher prevalence of renal manifestations among Hispanics (p = 0.006), 
neurologic manifestations among Blacks (p = 0.007), and hematologic manifestations 
among APIs (p = 0.015) lost their statistical significance. There were no statistically 
significant differences in prevalence between racial/ethnic minority groups and whites for 
the mucocutaneous, serositis, cardiovascular, pulmonary, gastrointestinal, musculoskeletal, 
or serologic manifestation categories. Appendix 2 shows the prevalence of individual 
manifestations within each category, stratified by race/ethnicity.
Time to development of severe manifestations of SLE.
Figure 1 displays Kaplan-Meier curves illustrating time to incident severe SLE 
manifestations following SLE diagnosis, stratified by race/ethnicity. Mean and median 
follow-up times were 12.5 and 9.8 years, respectively. Log-rank tests demonstrated 
statistically significant differences between race/ethnicities in the time to development of 
lupus nephritis (p < 0.01), thrombocytopenia (p = 0.04), APS (p < 0.01), and the combined 
outcome (p < 0.01), but not for neuropsychiatric lupus (p = 0.59). For all racial/ethnic 
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minorities, the risk in development of lupus nephritis, thrombocytopenia, APS, and the 
combined outcome was greatest in the first year after disease onset.
Cox proportional hazard regression results are displayed in Table 3. All racial/ethnic 
minorities with SLE had statistically significant increased hazard ratios relative to whites for 
lupus nephritis and thrombocytopenia. APIs and Hispanics had increased hazard ratios for 
APS, and Blacks and APIs had increased hazard ratios for the combined outcome relative to 
whites. There were no statistically significant differences in hazard ratios for 
neuropsychiatric lupus among the racial/ethnic groups. Relative to women, men with SLE 
had between 1.4 and 2.1 times the hazard ratio of lupus nephritis, thrombocytopenia, and the 
combined outcome. There were no statistically significant differences in hazard ratios for the 
severe SLE manifestations among the age at SLE diagnosis categories. Furthermore, there 
were no significant differences in the proportion of severe SLE manifestations identified at 
SLE diagnosis among race/ethnicities (data not shown).
Of the patients identified with lupus nephritis based on the primary variable definition, 76% 
had a diagnosis of lupus nephritis by the treating physician in their medical charts. A 
sensitivity analysis examining only individuals diagnosed with lupus nephritis by the 
treating physician revealed slightly reduced hazard ratios with preserved statistical 
significance for all racial/ethnic minority groups, except Blacks (p = 0.054) (Appendix 3).
DISCUSSION
Using a large, racial/ethnically diverse population-based registry, we identified racial/ethnic 
differences in the prevalence of SLE manifestations and in the risk and timing of 
development of severe SLE manifestations. This analysis demonstrates substantial 
differences in the prevalence of several clinical SLE manifestations among race/ethnicities. 
Blacks, APIs, and Hispanics had a greater prevalence of renal abnormalities in comparison 
to whites. In addition, Blacks had increased neurologic manifestations and both Blacks and 
APIs had increased hematologic manifestations in comparison to whites. These findings are 
not explained by racial/ethnic differences in sex, age at SLE diagnosis or duration of SLE 
disease, as all of these risk factors were accounted for in this analysis. We also found that 
Blacks, APIs, and Hispanics are at increased risk of developing a number of severe 
manifestations—lupus nephritis, thrombocytopenia, and APS—earlier than whites following 
SLE diagnosis. Men also developed lupus nephritis and thrombocytopenia earlier than 
women. Our study represents the first comprehensive examination of differences in SLE 
manifestations in API and Hispanic patients in the U.S., two racial/ethnic groups that have 
been understudied in population-based epidemiologic investigations.
We found that for racial/ethnic minorities, the risk of lupus nephritis was greatest during the 
first year following diagnosis of SLE. Subsequently, the annual risk of lupus nephritis 
remained approximately constant, with the highest burden of risk experienced by APIs. 
Whites, on the other hand, had a nearly constant incidence rate. The hazard ratios calculated 
in our analyses are consistent with those of at least one previous study, which also found 
increased risks for Blacks (HR = 1.5), Asians (HR = 1.8), and Hispanics (HR = 1.5) in 
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comparison to whites (6), although the hazard ratios in that study were not as large as 
discovered here.
There are several possible explanations for why racial/ethnic minority groups with SLE are 
at greater risk of developing lupus nephritis. Genetic factors have been proposed to explain 
why Blacks with SLE have a greater likelihood of renal disease, more severe disease 
presentation, and poorer prognosis relative to whites (13–16). A number of studies have also 
attributed worse outcomes among Black and Hispanic patients to socioeconomic factors, 
although no analysis has looked specifically at the association between socioeconomic 
factors and the onset of lupus nephritis (16–18). Surprisingly, the highest risk for lupus 
nephritis was observed among APIs, nearly double that of Blacks and Hispanics. This is 
despite the fact that APIs have the highest average levels of income and education and the 
best access to health care among racial/ethnic minority groups in San Francisco County (19), 
suggesting that there may be additional underlying factors that increase risk in this 
population. In Blacks, certain genotypes increase the risk of lupus nephritis, and although 
this is a potential mechanism among Asians, it remains understudied (20).
There are no previous studies describing the time to development of thrombocytopenia, 
neuropsychiatric lupus, or APS in patients with SLE. All racial/ethnic groups, including 
whites, were at greatest risk of thrombocytopenia and APS during the first year following 
SLE diagnosis, and continued to develop these manifestations throughout the follow-up 
period. It is plausible that genetic variation partially explains the observed racial/ethnic 
differences in the risk of APS. No defined racial/ethnic predominance for primary APS has 
been documented, but several studies support the increased risk conferred by various genetic 
variants, particularly human leukocyte antigen associations (21,22). Future studies 
investigating racial/ethnic group level differences in genetic variability are needed.
Numerous studies demonstrate that men with SLE are more likely to have organ damage, 
including renal disease and neuropsychiatric abnormalities, and have an increased mortality 
rate one year following initial SLE hospitalization (23–27). A previous analysis has shown 
that men develop lupus nephritis earlier than women, with a reported relative hazard of 1.7 
(6). Our results show similar findings, and that men had the greatest risk of lupus nephritis 
during the first year following diagnosis of SLE (data not shown). Furthermore, our results 
show that men develop thrombocytopenia earlier following SLE diagnosis, a result not 
previously demonstrated. Although our analysis does not readily identify causes for these 
differences, several theories exist to explain gender differences in SLE presentation, 
including differences in sex hormones and decreased medical-seeking behavior among men, 
possibly leading to their delayed diagnosis (28).
A potential contributor to the more severe progression of lupus identified in men relative to 
women and in the studied minority groups relative to whites could be that SLE is diagnosed 
at a more advanced stage in these populations. This would explain both the relatively 
accelerated appearance of lupus nephritis and thrombocytopenia occurring within the first 
year and why racial/ethnic minorities appear to have greater risk for development of several 
manifestations of SLE after controlling for duration of disease. There is some preliminary 
support for this hypothesis (28,29). In one study, compared with women, men had higher 
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risk of severe disease activity at the time of SLE diagnosis as determined by a SLEDAI 
score ≥ 12 independent of age, racial/ethnic group, anti-Ro positivity, or time to criteria 
accrual [OR 3.11 (95%CI: 1.09 – 8.92)] (29). Further work is needed to unravel the 
contribution of delayed access to diagnosis and treatment.
One of the major strengths of CLSP is the careful and systematic attention to case 
ascertainment using a variety of sources: university and community clinics, hospitals, 
regional laboratories, and state administrative databases. Asian and Hispanic patients were 
further identified through physicians focused on these populations (e.g. Chinese patients at 
San Francisco’s Chinese hospital) and through multilingual abstractors.
Several limitations to this study exist. There is always a potential for incomplete case 
ascertainment despite the efforts described above. Each clinic and hospital had to voluntarily 
agree to participate in CLSP. Unfortunately, two community hospitals in San Francisco 
chose not to participate in the program. Given the small number of cases identified solely 
through community-based hospitals, fewer than five cases were expected to be missing from 
this data (3). Incomplete case ascertainment might also have occurred because surveillance 
efforts were focused on rheumatology clinics and did not include primary care clinics. 
Capture-recapture analysis reported in a prior publication estimated an additional 147 
patients, though this estimation had a wide confidence interval (3). A second limitation is 
that the quality of medical record documentation of SLE manifestations and criteria varied 
widely depending on the clinic or hospital setting. Older charts that may have documented 
early manifestations of disease, particularly serologic laboratory results, were difficult to 
obtain and may have been inadequately captured. Third, race and ethnicity were determined 
from the medical record, not through patient self-report. Race and ethnicity were sometimes 
poorly documented in the medical records, leading to missing data for race and ethnicity. 
Importantly, this study also did not account for variables that historically have been 
associated with severe disease manifestations including socioeconomic status, medications, 
access to care, and coexisting medical conditions. The analysis of genetic and other biologic 
data would have been useful if collected previously for this study population. A longitudinal 
cohort study called the California Lupus Epidemiology Surveillance Study (CLUES) has 
emerged from analysis of biologic specimens voluntarily provided by members of the CLSP 
cohort.
This study found important differences in the characteristics and progression of SLE 
between racial/ethnic minority groups and whites. It is the first study to use rigorous 
epidemiologic methods to compare SLE manifestations across four racial/ethnic groups, 
including APIs and Hispanics, two understudied populations. Data collected in this study 
support the importance of increased awareness of SLE and its accelerated progression by 
clinicians for these racial/ethnic groups. These data also advocate for greater resource 
allocation on early diagnosis and treatment in these populations. Future studies should 
attempt to collect and analyze data on additional risk factors, including socioeconomic 
status, access to care, medication and appointment adherence, coexisting medical conditions, 
and genetic variation and the relationship of these variables to the onset of disease 
manifestations.
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Appendix 1.: Clinical manifestations of SLE, among prevalent SLE cases in 
San Francisco County, 2007 – 2009
Mucocutaneous    Pulmonary hemorrhage Hematologic
   Malar rash    Shrinking lung syndrome    Vascular thrombosis
   Discoid rash Gastrointestinal    Hemolytic anemia
   Subacute cutaneous LE    Peritonitis    Direct coomb’s test
   Bullous skin lesions    Pancreatitis    Antiphospholipid syndrome 
(APS)
   Panniculitis    Hepatitis    Leukopenia
   Alopecia Renal    Lymphopenia
   Cutaneous vasculitis    Dialysis    Thrombocytopenia
   Raynaud’s    Renal transplantation Serologies
   Livedo reticularis    Lupus nephritis    Lupus anticoagulant
   Urticaria    24 hour urine for protein (≥ 
500mg)
   Anticardiolipin antibodies
   Photosensitivity    Urine protein/creatinine > 0.5    Anti-beta 2 glycoprotein I
   Mucosal ulcers    Urine protein/creatinine > 3    Low C3
   Chilblain lupus    Urinalysis: protein    Low C4
   Lupus tumidus    Urinalysis: cellular casts    Low complement
   LE mucosus Musculoskeletal    ANA
   Maculopapular rash    Arthritis    Anti-ds DNA
   Toxic epidermal 
necrolysis
   Jaccoud’s arthropathy    Anti-Smith
Serositis    Avascular necrosis    Anti-Smith/RNP
   Serositis    Myositis    Anticardiolipin (aCL) antibodies 
(IgG)
   Pleuritis Neurological    Anticardiolipin (aCL) antibodies 
(IgM)
   Pericarditis    Seizures    Anti-beta2 glycoprotein I-IgG
   Peritonitis    Psychosis    Anti-beta2 glycoprotein I-IgM
Cardiovascular    Mononeuritis multiplex    Anticoagulant screen 
confirmatory test
   Pericarditis    Cerebrovascular disease    Anti-RNP
   Myocardial infarction    Transverse myelitis    Anti-Ro/SSA
Pulmonary    Aseptic meningitis    Anti-La/SSB
   Pulmonary hypertension    Chorea    RF
   Interstitial lung disease    Cranial and/or peripheral 
neuropathy
   Antiphospholipid (aPL) 
antibodies
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   Pneumonitis    Acute confusional state    Lupus anticoagulant confirmatory
Appendix 2.: Prevalence ratios for SLE manifestations stratified by race/
ethnicity, among prevalent SLE cases in San Francisco County, 2007 – 2009
Characteristic
Non-
Hispanic 
White (n 
= 189)
Non-Hispanic Black 
(n = 135) API (n = 265) Hispanic (n = 109)
PR (95% CI) PR (95% CI) PR (95% CI)
Mucocutaneous reference 0.98 (0.89 – 1.07) 1.04
(0.97 – 
1.11) 1.00
(0.91 – 
1.10)
  Malar rash reference 0.80 (0.62 – 1.03)
*1.23 (1.04 – 1.46) 1.02
(0.81 – 
1.29)
  Raynaud’s reference 0.91 (0.66 – 1.27) 1.21
(0.95 – 
1.55) 0.88
(0.62 – 
1.24)
  Cutaneous vasculitis reference 1.09 (0.54 – 2.18) 1.66
(0.97 – 
2.84) 0.78
(0.34 – 
1.80)
  Photosensitivity reference 1.06 (0.80 – 1.40) 1.09
(0.87 – 
1.37) 1.06
(0.79 – 
1.42)
  Discoid rash reference ***2.13 (1.39 – 3.26) 0.90
(0.57 – 
1.43) 0.58
(0.28 – 
1.21)
  Alopecia reference *1.37 (1.03 – 1.82)
*1.41 (1.10 – 1.79) 1.26
(0.94 – 
1.71)
  Livedo reticularis reference **0.16 (0.05 – 0.51) 1.42
(0.94 – 
2.13) 0.83
(0.45 – 
1.53)
  Maculopapular rash reference 0.65 (0.26 – 1.61) 1.49
(0.81 – 
2.74) 1.10
(0.50 – 
2.43)
  Mucocutaneous ulcer reference 0.77 (0.55 – 1.07) 0.93
(0.71 – 
1.20) 1.00
(0.73 – 
1.38)
Serositis reference 1.13 (0.92 – 1.38) 0.92
(0.76 – 
1.12) 1.09
(0.87 – 
1.37)
  Pleuritis reference 1.06 (0.83 – 1.35) 0.86
(0.68 – 
1.08) 1.18
(0.91 – 
1.52)
  Pericarditis reference 1.29 (0.86 – 1.95) 1.04
(0.71 – 
1.52) 1.29
(0.82 – 
2.04)
Cardiovascular reference 1.38 (0.95 – 2.01) 1.09
(0.77 – 
1.55) 1.34
(0.88 – 
2.04)
  Myocardial infarction reference 2.17 (0.92 – 5.14) 1.33
(0.58 – 
3.09) 1.83
(0.62 – 
5.42)
Pulmonary reference 1.09 (0.87 – 1.36) 0.96
(0.78 – 
1.17) 1.13
(0.89 – 
1.44)
  Pulmonary 
hypertension
reference 2.12 (0.96 – 4.71)
*2.60 (1.32 – 5.11) 2.04
(0.87 – 
4.77)
  Interstitial lung disease reference 1.92 (0.86 – 4.32) 1.46
(0.67 – 
3.21) 1.94
(0.78 – 
4.84)
Gastrointestinal reference 1.64 (0.84 – 3.18) 1.30
(0.71 – 
2.37) 1.71
(0.85 – 
3.44)
Renal reference ***1.74 (1.40 – 2.16)
***1.68 (1.38 – 2.05)
*1.35 (1.05 – 1.74)
  Lupus nephritis reference ***1.76 (1.24 – 2.48)
***2.11 (1.56 – 2.85)
*1.50 (1.01 – 2.21)
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Characteristic
Non-
Hispanic 
White (n 
= 189)
Non-Hispanic Black 
(n = 135) API (n = 265) Hispanic (n = 109)
PR (95% CI) PR (95% CI) PR (95% CI)
  Dialysis reference **2.53 (1.36 – 4.70)
*1.92 (1.08 – 3.42) 1.57
(0.72 – 
3.41)
Musculoskeletal reference 1.00 (0.91 – 1.11) 0.95
(0.87 – 
1.04) 1.07
(0.97 – 
1.18)
  Nonerosive arthritis reference 0.95 (0.85 – 1.06) 0.94
(0.86 – 
1.03) 1.07
(0.97 – 
1.18)
Neurologic reference *1.49 (1.12 – 1.98) 0.76
(0.56 – 
1.04) 0.98
(0.67 – 
1.44)
  Seizures reference 1.44 (0.85 – 2.44) 0.75
(0.43 – 
1.28) 0.99
(0.51 – 
1.94)
  Psychosis reference 1.72 (0.82 – 3.61) 0.80
(0.36 – 
1.78) 0.74
(0.27 – 
2.03)
  Cerebrovascular 
disease
reference *1.95 (1.11 – 3.42) 0.98
(0.55 – 
1.77) 0.89
(0.37 – 
2.16)
  Neuropathy reference 0.78 (0.42 – 1.45)
*0.44 (0.24 – 0.83) 0.55
(0.24 – 
1.22)
Hematologic reference ***1.09 (1.04 – 1.15)
*1.07 (1.01 – 1.13) 1.06
(1.00 – 
1.13)
  Vascular thrombosis reference ***2.24 (1.55 – 3.24) 0.86
(0.56 – 
1.32) 1.45
(0.88 – 
2.39)
  Hemolytic anemia reference 2.24 (0.97 – 5.17)
*2.19 (1.04 – 4.64)
***3.66 (1.68 – 7.94)
  Coombs reference *2.94 (1.26 – 6.85) 2.15
(0.96 – 
4.82)
**3.35 (1.45 – 7.75)
  APS reference 1.32 (0.76 – 2.30) 1.48
(0.93 – 
2.35) 1.51
(0.89 – 
2.56)
  Leukopenia reference **1.28 (1.08 – 1.51)
***1.29 (1.11 – 1.49) 1.20
(1.00 – 
1.45)
  Lymphopenia reference *1.10 (1.01 – 1.20) 1.08
(1.00 – 
1.17) 1.06
(0.95 – 
1.18)
  Thrombocytopenia reference ***1.93 (1.38 – 2.70)
*1.51 (1.10 – 2.07)
**1.73 (1.19 – 2.52)
Serologic reference 1.00 (1.00 – 1.01) 1.00
(1.00 – 
1.01) 1.00
(1.00 – 
1.01)
  ANA reference 1.04 (0.98 – 1.10) 1.00
(0.94 – 
1.06) 1.00
(0.93 – 
1.08)
  Anti-DNA/Anti-
dsDNA
reference 1.10 (0.91 – 1.33)
***1.37 (1.19 – 1.59)
**1.27 (1.06 – 1.51)
  Lupus anticoagulant reference *1.46 (1.07 – 2.00) 1.05
(0.78 – 
1.42) 1.09
(0.75 – 
1.60)
  Anti-B2GP1 reference 0.60 (0.18 – 1.96) 0.62
(0.24 – 
1.58) 2.24
(0.95 – 
5.23)
  Low C3 reference 1.01 (0.79 – 1.29)
***1.58 (1.32 – 1.88) 1.24
(0.99 – 
1.56)
  Low C4 reference 0.94 (0.74 – 1.21)
*1.21 (1.01 – 1.47)
*1.26 (1.01 – 1.58)
  Hypocomplementemia reference 0.85 (0.70 – 1.04)
**1.23 (1.08 – 1.41) 1.08
(0.91 – 
1.29)
  Anti-Smith reference ***3.14 (1.94 – 5.09)
***2.20 (1.37 – 3.53)
*1.78 (1.03 – 3.07)
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Characteristic
Non-
Hispanic 
White (n 
= 189)
Non-Hispanic Black 
(n = 135) API (n = 265) Hispanic (n = 109)
PR (95% CI) PR (95% CI) PR (95% CI)
  Anti-SmRNP reference ***2.79 (1.68 – 4.65)
**1.95 (1.19 – 3.20) 1.57
(0.87 – 
2.85)
  Anti-RNP reference ***2.21 (1.42 – 3.43)
***2.18 (1.44 – 3.28)
*1.84 (1.14 – 2.97)
  Anti-RoSSA reference 1.42 (0.95 – 2.12)
***1.94 (1.39 – 2.71)
**1.70 (1.14 – 2.53)
  Anti-RoSSB reference 1.10 (0.88 – 1.37)
*1.25 (1.04 – 1.50) 1.16
(0.91 – 
1.46)
  RF reference 1.65 (0.83 – 3.28)
*1.85 (1.01 – 3.39)
***3.14 (1.66 – 5.95)
  ACLAPL IgG reference 1.33 (0.83 – 2.14) 1.17
(0.77 – 
1.78) 1.34
(0.83 – 
2.16)
  ACLAPL IgM reference 0.82 (0.43 – 1.57) 0.97
(0.59 – 
1.59)
*1.84 (1.10 – 3.08)
  Antiphospholipid Ab reference 1.24 (0.99 – 1.55) 1.09
(0.89 – 
1.33) 1.16
(0.91 – 
1.49)
Calculations based on Poisson regression model with robust error variances using the following risk factors: sex, age at 
SLE diagnosis, and years since SLE diagnosis.
*
alpha < 0.05
**
alpha < 0.005
***
alpha < 0.001. Manifestations with less than 35 observations are not shown. API = Asian/Pacific Islander.
Appendix 3.: Sensitivity analysis of physician-diagnosed lupus nephritis in 
multivariable Cox proportional hazards regression, among prevalent SLE 
cases in San Francisco County, 2007 – 2009
Lupus Nephritis
Race/ethnicity HR (95% CI)
  Non-Hispanic White reference
  Non-Hispanic Black 1.7 (0.99 – 2.7)
  API 3.7 (2.5 – 5.7)
  Hispanic 1.8 (1.03 –3.2)
Calculations based on Cox proportional hazards model that contained each of race/ethnicity, sex, and age at diagnosis.
API = Asian/Pacific Islander. HR = hazard ratio. Higher hazards indicate a shorter time to development of specific 
manifestations.
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Significance and Innovation
• Relative to whites, racial/ethnic minority groups (Blacks, Asian/Pacific 
Islanders, and Hispanics) develop more renal, neurologic, and hematologic 
manifestations. They also develop lupus nephritis, thrombocytopenia, and 
APS sooner.
• It is the first study to use rigorous epidemiologic methods to compare SLE 
manifestations across four racial/ethnic groups, including APIs and Hispanics, 
two understudied populations.
• Data collected in this study support the importance of increased awareness of 
SLE and its accelerated progression by clinicians for these racial/ethnic 
groups.
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Figure 1. 
Time to incident severe SLE manifestation following SLE diagnosis, stratified by race/
ethnicity, among prevalent SLE cases in San Francisco County, 2007 – 2009
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